Merck and Large Pharmas Best Days Are Behind Them! - Avis employé Principal Engineer Merck

1,0
3 juil. 2009
Recommande
Approbation du PDG
Perspective commerciale

Avantages

I've worked with some of the BEST talent in chemical engineering, analytical research, and process chemistry during my 33+ years at Merck. Merck has a generous benefits package including a defined pension, 401K match, and health benefits. Merck has a 100% tuition assistance program for obtaining advanced degrees. They offer a 2-year PhD program that allows you to go to school full time for two years so you can complete your PhD research thesis. Many rotational assignments are offered so you can move through different working groups and projects to gain "hands on" experience

Inconvénients

Merck has not been a growth comapny for over ten years. It sales and revenues continue to fall. Over the last five years 20,000 employee positions have been cut world wide. With the Merck-Schering Plough Merger (4Q2009) an additional 20% of the combined companies head count will be cut resulting in an additiional 20,000+ staff reductions. More cuts and plant closings are planned for 2010-2011.The drug pipeline is weak with several Phase III Compounds being discontinued and NDA's being withdrawn from FDA review. Several key drugs are coming off patent in 2010 and 2012. Many research jobs and drug production is being shifted to India and China.

Découvrez plus d’avis sur Merck

5,0
30 juin 2026
Recommande
Approbation du PDG
Perspective commerciale

Avantages

Excellent company to work with.

Inconvénients

No cons encountered so far

4,0
30 juin 2026
Recommande
Approbation du PDG
Perspective commerciale

Avantages

Great benefits like medical/dentist/vision, pension, stock option, 401k match. Co workers are excellent, pretty good on site symposiums, lot of diversity clubs/activities. Innovation is extremely welcomed. Diversity in research portfolio. AI/ML is heavily invested to make databases more efficient.

Inconvénients

Micro managing, especially within the biologics department, potentially others. Promotions are limited, and pay bump is poor. Company invests too much in buying companies rather than keeping talent - lay offs let go of great talented people. Merck is afraid of investing into exploratory biology and doesn’t take risk - they even admit they would rather see other companies clinical data or R&D data rather than taking a risk. Although it’s slow going in building new software, current databases are slow and needs much improvement. Extremely poor work/life balance.

Voir les avis par: Utile|Évaluation|Date|Tout